NCT01129258已完成1 期
A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Safety Endpoints: Safety and tolerability of PF-04991532 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, and clinical safety laboratory measurements.
研究概览
简要总结
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04991532 following multiple (14 days) escalating oral doses in patient wtih type 2 diabetes.
详细描述
Safety/Tolerability, PK, and PD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes mellitus who are taking metformin only. Treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 2 months. Subjects treated with a sulfonylurea (SU) or a dipeptidyl peptidase-4 inhibitor (DPP-4i) in combination with metformin may be eligible if washed off the SU or DPP-4i to metformin only for a minimum of 4 weeks before dosing. Subjects being switched over from an SU and metformin or a DPP-4i and metformin to metformin only will still need to meet the fasting glucose requirements on Day -2 as defined in the protocol.
- •Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).
- •Fasting C-peptide >0.8 ng/mL.
- •HbA1c >/=7% and >/=10%. If the patient requires to be washed off an SU or DPP-4i, the HbA1c limits will be >/=6.5% and </=9%.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Subjects who have chronic conditions other than T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either diet or stable (for the last 2 months) doses of medications may be included as well.
- •Evidence or history of diabetic complications with significant end-organ damage.
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
- •History of stroke, transient ischemic attack, or myocardial infarction within the past 6 months.
- •History of coronary artery bypass graft or stent implantation.
- •Clinically significant peripheral vascular disease.
- •Any history or clinical evidence of congestive heart failure, NYHA Classes II-IV.
- •Current history of angina/unstable angina.
- •ECG findings suggestive of asymptomatic myocardial ischemia or QTc >470 msec at screening.
- •One or more self-reported episodes of hypoglycemia within the last 3 months, or two or more self-reported episodes of hypoglycemia within the last 6 months.
- •Screening or Day -2 fasting (>/=8 hours) glucose, </=90 or >/=270 mg/dL, confirmed by a single repeat if deemed necessary.
- •A positive urine drug screen.
- •Use of tobacco or nicotine-containing products in excess of the equivalent of 10 cigarettes per day.
- •History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
- •Certain concomitant medications are excluded, as defined in the protocol.
- •Screening supine blood pressure >/=160 mm Hg (systolic) or >/=100 mm Hg (diastolic).
- •Certain laboratory values (for example, triglyceride and liver function test results).
- •Pregnant or nursing females; females of childbearing potential.
研究组 & 干预措施
PF-04991532
Experimental
干预措施: PF-04991532 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety Endpoints: Safety and tolerability of PF-04991532 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, and clinical safety laboratory measurements.
时间窗: 5 months
Single-Dose PK Endpoints for PF-04991352: Cmax, Tmax, and AUC(0-tau).
时间窗: 5 months
Multiple-Dose PK Endpoints for PF-04991532: Cmax(ss), Tmax(ss), AUC(0-tau,ss), AUC(0-last), half-life, Cmin(ss), Cav(ss), Ae%, CL/F, Vz/F, CLrenal; accumulation ratios AUC(0-tau,ss)/AUC(0-tau,sd) and Cmax(ss)/Cmax(sd), as the data permit.
时间窗: 5 months
PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.
时间窗: 5 months
次要结局
- Insulin and C-peptide (changes from Day -1 baseline) during an MMTT on Days 1 and 14.(5 months)
- Mean daily glucose (change from Day -1 baseline) on Days 1 and 14.(5 months)
- Fasting plasma glucose (change from Day -1 baseline) on Days 1, 3, 6, 10, and 14.(5 months)
- Lipids (change from Day -1 baseline), including: TG, TC, HDL-cholesterol, LDL-cholesterol, FFA, beta-OHB, and ACAC, at times specified in the SOA.(5 months)
- Lactate (change from Day -1 baseline), at times specified in the SOA.(5 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Dose Study Of PF-04937319 In Patients With Type 2 DiabetesNIDDMDiabetes Mellitus, Type 2NCT01272804Pfizer61
已完成
1 期
Single Dose Study of PF-04991532 in Healthy SubjectsGlucose Metabolism DisordersDiabetes MellitusDiabetes Mellitus, Type 2NCT01102673Pfizer18
已完成
1 期
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01044537Pfizer50
已完成
1 期
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic PatientsDiabetes Mellitus, Type 2NCT01396161Pfizer64
已完成
1 期
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus PatientsDiabetes Mellitus, Type 2NCT01856595Pfizer117